Follow
Janice Reichert
Janice Reichert
The Antibody Society
Verified email at reichertbiotechconsulting.com
Title
Cited by
Cited by
Year
Development trends for human monoclonal antibody therapeutics
AL Nelson, E Dhimolea, JM Reichert
Nature reviews drug discovery 9 (10), 767-774, 2010
12742010
Monoclonal antibody successes in the clinic
JM Reichert, CJ Rosensweig, LB Faden, MC Dewitz
Nature biotechnology 23 (9), 1073-1078, 2005
10782005
Bispecific antibodies: a mechanistic review of the pipeline
AF Labrijn, ML Janmaat, JM Reichert, PWHI Parren
Nature reviews Drug discovery 18 (8), 585-608, 2019
9652019
Future directions for peptide therapeutics development
AA Kaspar, JM Reichert
Drug discovery today 18 (17-18), 807-817, 2013
8472013
Development trends for monoclonal antibody cancer therapeutics
JM Reichert, VE Valge-Archer
Nature Reviews Drug Discovery 6 (5), 349-356, 2007
5352007
Antibodies to watch in 2019
H Kaplon, JM Reichert
MAbs 11 (2), 219-238, 2019
4592019
Recombinant protein therapeutics—success rates, market trends and values to 2010
AK Pavlou, JM Reichert
Nature biotechnology 22 (12), 1513-1519, 2004
4552004
Marketed therapeutic antibodies compendium
JM Reichert
MAbs 4 (3), 413-415, 2012
4532012
Antibodies to watch in 2020
H Kaplon, M Muralidharan, Z Schneider, JM Reichert
MAbs 12 (1), 1703531, 2020
4282020
Development trends for therapeutic antibody fragments
AL Nelson, JM Reichert
Nature biotechnology 27 (4), 331-337, 2009
3992009
Antibodies to watch in 2013: Mid-year update
JM Reichert
MAbs 5 (4), 513-517, 2013
393*2013
Trends in development and approval times for new therapeutics in the United States
JM Reichert
Nature reviews Drug discovery 2 (9), 695-702, 2003
3312003
Monoclonal antibodies as innovative therapeutics
JM Reichert
Current pharmaceutical biotechnology 9 (6), 423-430, 2008
3242008
Antibody-based therapeutics to watch in 2011
JM Reichert
MAbs 3 (1), 76-99, 2011
3132011
Antibodies to watch in 2017
JM Reichert
MAbs 9 (2), 167-181, 2017
3022017
Monoclonal antibodies in the clinic
JM Reichert
Nature biotechnology 19 (9), 819-822, 2001
2962001
Antibodies to watch in 2021
H Kaplon, JM Reichert
MAbs 13 (1), 1860476, 2021
2842021
Antibodies to watch in 2018
H Kaplon, JM Reichert
MAbs 10 (2), 183-203, 2018
2832018
Antibodies to watch in 2022
H Kaplon, A Chenoweth, S Crescioli, JM Reichert
MAbs 14 (1), 2014296, 2022
2762022
Marketing approval of mogamulizumab: a triumph for glyco-engineering
A Beck, JM Reichert
MAbs 4 (4), 419-425, 2012
2392012
The system can't perform the operation now. Try again later.
Articles 1–20